Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman & That He Will Not Stand for Re-Election to the Board of Directo...
29 Março 2016 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
Mr. Thomas Lynch, non-executive chairman of the board of directors,
has notified ICON that he will retire as chairman on 31 March 2016
and will not stand for re-election to the board at the company’s
annual general meeting in July 2016. Mr. Lynch has been a
non-executive director of ICON since 1994 and served as senior
independent director from 2010 to 2012 and as chairman since
January 2013.
Mr. Lynch commented “Having served as chairman since January
2013, I believe the timing is right for me to relinquish the chair
so that I can focus more on other responsibilities and
opportunities outside of ICON. In addition, as my current term as a
director will expire at the company’s annual general meeting in
July 2016, I have decided not to stand for a further term and will
retire from the board at the annual general meeting. I retire from
the ICON board after twenty two years in July next with great
satisfaction with ICON's growth and success over that period and am
proud of its emergence as a global industry leading clinical
research organisation. It has been a privilege to have worked with
the ICON leadership teams over those years. I wish ICON every
success in the future."
On behalf of the board, ICON’s chief executive officer, Mr.
Ciaran Murray, commented “Thomas has made a significant
contribution to the ICON board in his 22 years as a non-executive
director. His deep knowledge of the pharmaceutical industry has
been a valuable asset to the board during his long and
distinguished board service. The ICON board wishes him all the best
with his future endeavours.”
ICON’s senior independent director, Mr. Declan McKeon, will
serve as acting chairman from Mr. Lynch’s retirement as chairman
and the board will initiate a process to appoint a new
chairman.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 90 locations in 37 countries and has approximately
11,900 employees. Further information is available at
www.iconplc.com.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160329005633/en/
ICON plcInvestor Relations, 1-888-381-7923orBrendan Brennan, +
353 –1-291-2000Chief Financial OfficerorSimon Holmes, + 353
–1-291-2000EVP Investor Relations and Corporate Development
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024